Targeting Cancer at the Nuclear Pore

Article Tools UNDERSTANDING THE PATHWAY Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES First-in-Class, First-in-Human Phase I Study of Selinexor, a Selective Inhibitor of Nuclear Export, in Patients With Advanced Solid Tumors. February 29, 2016 ARTICLE CITATION DOI: 10.1200/JCO.2016.67.5637 Journal of Clinical Oncology - published online before print October 26, 2016 PMID: 27863200 Targeting Cancer at the Nuclear Pore Asfar S. AzmixAsfar S. AzmiSearch for articles by this author and Ramzi M. MohammadxRamzi M. MohammadSearch for articles by this author Show More Asfar S. Azmi and Ramzi M. Mohammad, Wayne State University School of Medicine, Detroit, MI https://doi.org/10.1200/JCO.2016.67.5637 First Page Full Text PDF Figures and Tables © 2016 by American Society of Clinical Oncology Companion First-in-Class, First-in-Human Phase I Study of Selinexor, a Selective Inhibitor of Nuclear Export, in Patients With Advanced Solid Tumors